Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

Abstract Background This study aims to assess the sustained immunological response to the SARS-CoV-2 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIRD) undergoing different treatment regimens. Methods We conducted a prospective observational study involving 157 AIRD patients...

Full description

Bibliographic Details
Main Authors:	Silvia Garcia-Cirera, Joan Calvet, Juan Francisco Delgado de la Poza, Antoni Berenguer-Llergo, Cristóbal Orellana, Menna Rusiñol, Maria Llop, Marta Arévalo, Alba Garcia-Pinilla, Ester Costa, Cristina Aymerich, Rafael Gómez, Anna Carreras, Jordi Gratacós
Format:	Article
Language:	English
Published:	BMC 2024-01-01
Series:	European Journal of Medical Research
Subjects:	Autoimmune disease Immune response COVID19 Neutralizing antibodies
Online Access:	https://doi.org/10.1186/s40001-023-01620-7

Similar Items

Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping
by: Joan Calvet, et al.
Published: (2024-01-01)

Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
by: Silvia Garcia-Cirera, et al.
Published: (2022-08-01)

Synovial fluid but not plasma interleukin-8 is associated with clinical severity and inflammatory markers in knee osteoarthritis women with joint effusion
by: María García-Manrique, et al.
Published: (2021-03-01)

CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study
by: Joan Calvet, et al.
Published: (2020-11-01)

Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study
by: Maxime Dougados, et al.
Published: (2024-02-01)

Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission
by: Joan Calvet, et al.
Published: (2022-01-01)

Glucocorticoid-induced osteoporosis in rheumatic diseases
by: Rosa Maria Rodrigues Pereira, et al.
Published: (2010-01-01)

Uveitis in peripheral spondyloarthritis patients: an ancillary analysis of the ASAS-PerSpA study
by: Maria Llop, et al.
Published: (2022-09-01)

“Neuroimmunoendocrinology” in Children with Rheumatic Diseases: How Glucocorticoids Are the Orchestra Director
by: Maria Cristina Maggio, et al.
Published: (2023-08-01)

Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment
by: Andrea Delle Sedie, et al.
Published: (2011-09-01)

Current aspects of glucocorticoid therapy of rheumatic diseases. Pulse-therapy
by: S K Solov'ev, et al.
Published: (2009-06-01)

Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO
by: Maria Llop, et al.
Published: (2022-01-01)

Anti-inflammatory drugs and immunogenicity of vaccines in patients with rheumatic diseases
by: B. S. Belov, et al.
Published: (2021-12-01)

Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases
by: N. V. Chichasova
Published: (2016-01-01)

Perioperative Management of Patients with Rheumatic Diseases: Glucocorticoids, DMARDs, Biological Agents and NSAIDs
by: V. V. Lyalina, et al.
Published: (2022-02-01)

Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases
by: van der Klis F, et al.
Published: (2011-09-01)

Incident vertebral fractures 12 months following glucocorticoid initiation in children with rheumatic disorders
by: Lang Bianca A, et al.
Published: (2012-07-01)

Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study
by: M. Rossini, et al.
Published: (2017-05-01)

Immunogenicity and safety of vaccination in children with paediatric rheumatic diseases: a scoping review
by: Jacqueline Cunninghame, et al.
Published: (2023-04-01)

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
by: Yi-Qing Zheng, et al.
Published: (2022-10-01)

Roastgsa: a comparison of rotation-based scores for gene set enrichment analysis
by: Adrià Caballé-Mestres, et al.
Published: (2023-10-01)

Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database
by: Marta Arévalo, et al.
Published: (2018-10-01)

Correction to: Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database
by: Marta Arévalo, et al.
Published: (2020-06-01)

ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
by: M. S. Naumtseva, et al.
Published: (2016-02-01)

Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
by: Adriana Coracini Tonacio, et al.
Published: (2021-11-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases
by: D. V. Bukhanova, et al.
Published: (2018-07-01)

Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases
by: Nádia Emi Aikawa, et al.
Published: (2022-04-01)

Evaluation of the effectiveness of intra-articular injections of glucocorticoids in knee synovitis in patients with rheumatic diseases in real clinical practice
by: A. E. Karateev, et al.
Published: (2022-03-01)

The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial
by: Madeleine Rooney, et al.
Published: (2019-07-01)

Magnocellular Vasopressin and the Mechanism of “Glucocorticoid Escape”
by: Ferenc A. Antoni
Published: (2019-06-01)

Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis
by: Kuo-Tung Tang, et al.
Published: (2022-04-01)

A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
by: Deepak Nagra, et al.
Published: (2023-11-01)

Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease
by: Adegbenga Bankole, et al.
Published: (2023-07-01)

Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.
by: Jun Won Park, et al.
Published: (2020-01-01)

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
by: Huiqiong Zeng, et al.
Published: (2022-11-01)

Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases
by: Porntip Intapiboon, et al.
Published: (2022-11-01)

Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
by: Clovis A. Silva, et al.
Published: (2022-10-01)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
by: Catherine E. Raptis, et al.
Published: (2022-10-01)

Scrutinizing the Relationship between Subjective Anomalous Experiences and Psychotic Symptoms
by: Álex Escolà-Gascón, et al.
Published: (2022-05-01)